

Press
release

Montpellier, July 11th 2019 – 08h00 CEST

2019 Half -Year Results: strong growth in all financial indicators and convertible bonds contract suspension maintained

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and Myrian® designer, releases its 2019 half-year financial results approved by the Board on July 10th, 2019.

Efficiency and results of the new strategy

Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.

Operational breakeven has been achieved in 2018 and is confirmed over this first 2019 semester:

- Revenue: €1,580 k (+23.69%)
- EBITDA: €16 k (+107.02%)
- EBIT: €65 k (+108.48%)
- Net Income: €98.4 k (+111.03%)

First semester results fully benefit from the restructuring carried out during 2018.

Nicolas Reymond, CEO of Intrasense indicates: *“we are pursuing with enthusiasm and conviction the deployment of our strategy of company turnaround. After a year of restructuring in 2018 and the operational breakeven achievement, we are keeping the same dynamics. Reaching breakeven on net income in the first half of 2019 is a very positive indicator to pursue the execution of our plan, demonstrating the relevance of our approach.”*



2019 – 2020: consolidation and growth

The first positive results of 2018 are confirmed and reinforced during this first half year with an acceleration of business development in European and Chinese markets and the signature of commercial and innovation partnerships, demonstrating the relevance of the company's strategy.

At the same time, Intrasense continues to enrich its clinical applications portfolio thanks to significant investments in R&D, working on a new version of its Myrian® platform, which will be available in the third quarter of 2019. It will bring new clinical applications to the markets such as mammography, which has been certified within the second quarter of 2019.

Innovation remains at the heart of the company, which is deploying in 2019 a new cloud service offering as well as commercializing a first portfolio of artificial intelligence solutions with the objective of strengthening its market position.

Intrasense is pursuing the deployment of its strategy in its various markets, with a consolidation of its position in Europe, a validation of its positioning and strengthening of its visibility in the United States and pursuing its partnership approach with industrial companies and start-ups in the Chinese market.

New suspension of the convertible bonds contract

Given those 2019 half-year results and the perspectives of the company, following the first six-month suspension period announced on [January 28th, 2019](#) until July 27th, 2019, the company announces a new suspension period of automatic convertible bonds based on the contract signed on August 27th, 2018 with Luxembourg European High Growth Opportunities Securitization Fund.

The automatic tranches of 125,000 euros every twenty-five trading days are thus suspended again from July 26th, 2019 and until further notice.

Nicolas Reymond comments: *“Our cash flow management remains a high priority and will be a key element in the second half of the year, combined with ensuring key investments to build tomorrow growth while preserving the interests of our shareholders. Our financial results are very encouraging, and we are today building the future growth of Intrasense.”*



About Intrasense™

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

Contacts

Intrasense
Nicolas Reymond
Chief Executive Officer
1231 avenue du Mondial 98, 34000
Montpellier, FRANCE
Tel: +334 67 130 130
investor@intrasense.fr

NewCap
Investor Relations and Financial
Communication
Roxane Gbedigro

Tel: +331 44 71 94 94
intrasense@newcap.eu

